Unlike autologous cell therapy, where the patient’s own cells are used, allogeneic cell therapy companies leverage donor cells, which can come from various sources such as bone marrow or umbilical cord blood. In allogeneic cell therapy, healthy donor cells are harvested, processed, and then infused into the patient. These donor cells can differentiate into various […]
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.
To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.
Prime editing, a more advanced version of CRISPR/Cas9 technology, has been greenlit by the FDA to begin the first-ever clinical trial for this technology.
As we observed IgA Nephropathy Awareness Day on May 14th, let us take a look at ongoing clinical trials for drugs that aim to make patient lives better.
BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases.